Published in J Clin Oncol on March 01, 1991
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov (2012) 4.30
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol (2008) 2.23
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol (2008) 1.86
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 1.60
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer (1999) 1.50
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs (2008) 1.30
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int J Pharm (2011) 1.20
A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. Cancer Chemother Pharmacol (2011) 1.15
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol (2008) 1.01
Pharmacogenomics of human ABC transporter ABCC11 (MRP8): potential risk of breast cancer and chemotherapy failure. Anticancer Agents Med Chem (2010) 0.99
Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol (2009) 0.99
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol (2016) 0.98
Homo sapiens systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) protein mediates contact-dependent small RNA transfer and microRNA-21-driven chemoresistance. J Biol Chem (2011) 0.98
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer (1996) 0.97
Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo. Biomaterials (2009) 0.96
New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer (1998) 0.96
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer (2005) 0.94
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol (2009) 0.94
Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma. Cancer Lett (2011) 0.93
A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs (1997) 0.93
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer (1993) 0.92
Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs (1997) 0.92
Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol (2005) 0.90
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC Cancer (2012) 0.88
Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer (2005) 0.88
Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer (2003) 0.87
Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Mol Cancer Ther (2013) 0.87
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol (2015) 0.87
Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol (2006) 0.86
Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol (2007) 0.86
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol (2011) 0.86
Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther (2009) 0.86
5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorg Med Chem (2013) 0.85
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. Int J Cancer (2013) 0.85
Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer (2007) 0.84
Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World. Breast Care (Basel) (2008) 0.84
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res (2015) 0.83
Noncanonical self-assembly of highly asymmetric genetically encoded polypeptide amphiphiles into cylindrical micelles. Nano Lett (2014) 0.83
Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs (2000) 0.82
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS One (2013) 0.82
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol (2010) 0.82
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol (2016) 0.82
A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma. Invest New Drugs (2002) 0.81
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein. BMC Cancer (2014) 0.81
Synthesis and restriction enzyme analysis of oligodeoxyribonucleotides containing the anti-cancer drug 2',2'-difluoro-2'-deoxycytidine. Nucleic Acids Res (1992) 0.81
Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment. AAPS PharmSciTech (2010) 0.81
Pharmacogenetics of human ABC transporter ABCC11: new insights into apocrine gland growth and metabolite secretion. Front Genet (2013) 0.81
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. Invest New Drugs (2013) 0.80
Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial. Trials (2011) 0.80
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. Br J Cancer (2013) 0.79
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br J Cancer (2007) 0.79
INDs for PET molecular imaging probes-approach by an academic institution. Mol Imaging Biol (2014) 0.79
Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Antivir Chem Chemother (2014) 0.79
Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer. Clin Med Insights Oncol (2011) 0.78
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study. Invest New Drugs (2007) 0.78
Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B (2005) 0.78
Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B (2007) 0.78
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol (2008) 0.78
Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Clin Exp Nephrol (2011) 0.77
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol (2005) 0.77
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs (2011) 0.77
Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure. Pharmaceutics (2013) 0.77
Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer. Acta Pharmacol Sin (2010) 0.77
Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines. J Exp Clin Cancer Res (2009) 0.76
Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance. Antimicrob Agents Chemother (1998) 0.76
Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs (2001) 0.76
Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients. Transl Oncol (2014) 0.76
Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). PLoS One (2015) 0.76
Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol Pharm (2014) 0.76
Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials. Diagn Pathol (2014) 0.75
Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study. Can Vet J (2016) 0.75
Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue. Br J Cancer (1998) 0.75
Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. J Exp Clin Cancer Res (2010) 0.75
Molecular biology: Salvaging the genome. Nature (2015) 0.75
Phase I study of gemcitabine using a once every 2 weeks schedule. Br J Cancer (1997) 0.75
A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study. Cancer Res Treat (2004) 0.75
Gemcitabine-based chemotherapy in colon squamous cell carcinoma: A case report and literature review. Mol Clin Oncol (2017) 0.75
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Invest New Drugs (2015) 0.75
Preparation and evaluation of polymeric microparticulates for improving cellular uptake of gemcitabine. Int J Nanomedicine (2012) 0.75
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. Br J Cancer (2006) 0.75
Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig model. PLoS One (2013) 0.75
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors. Invest New Drugs (2015) 0.75
PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Invest New Drugs (1999) 0.75
A phase I study of topotecan and gemcitabine in advanced solid tumors. Invest New Drugs (2010) 0.75
Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study. Invest New Drugs (2005) 0.75
A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine (Taipei) (2017) 0.75
Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: on a daily x 5-day schedule. Invest New Drugs (1999) 0.75
Effective Encapsulation and Biological Activity of Phosphorylated Chemotherapeutics in Calcium Phosphosilicate Nanoparticles for the Treatment of Pancreatic Cancer. Nanomedicine (2017) 0.75
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med (1971) 3.82
Spin transfer torques in MnSi at ultralow current densities. Science (2010) 3.64
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (1996) 2.75
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Plantarflexor weakness as a limiting factor of gait speed in stroke subjects and the compensating role of hip flexors. Clin Biomech (Bristol, Avon) (1999) 2.59
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol (1995) 2.57
Detection and characterization of multiple forms of simian virus 40 large T antigen. J Virol (1981) 2.54
Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins. Virology (1984) 2.48
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Cancer of the breast: a study of 1520 consecutive patients operated on between 1960 and 1980. Can J Surg (1991) 2.06
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol (1995) 1.89
Physical mapping of human cytomegalovirus genes: identification of DNA sequences coding for a virion phosphoprotein of 71 kDa and a viral 65-kDa polypeptide. Virology (1984) 1.81
2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol (2001) 1.79
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst (1993) 1.77
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev (1993) 1.74
Analysis of the clinical factors determining natural and maximal gait speeds in adults with a stroke. Am J Phys Med Rehabil (1999) 1.74
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol (1994) 1.64
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res (1999) 1.60
Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest (1990) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
Phase shifts of the human circadian system and performance deficit during the periods of transition: I. East-west flight. Aerosp Med (1966) 1.50
How can we identify the best implantation site for an ECG event recorder? Pacing Clin Electrophysiol (2000) 1.50
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50
Measurement of the W boson mass with the D0 detector. Phys Rev Lett (2012) 1.46
Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J Antimicrob Chemother (2012) 1.45
Maximal grip force in chronic stroke subjects and its relationship to global upper extremity function. Clin Rehabil (1999) 1.43
[Polyostotic fibrous dysplasia of the spinal column and ribs]. Dtsch Med Wochenschr (1993) 1.40
Auxiliary rat liver transplantation with portal vein arterialization in acute hepatic failure. Transplantation (2000) 1.39
Survival of breast-cancer patients with previous or subsequent neoplasms. Can J Surg (1992) 1.39
Topographical and physicochemical modification of material surface to enable patterning of living cells. Crit Rev Biotechnol (2001) 1.38
Measurement of the nucleon strange-antistrange asymmetry at next-to-leading order in QCD from NuTeV Dimuon data. Phys Rev Lett (2007) 1.38
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) (1996) 1.37
Immunization of HIV-infected children with varicella vaccine. J Pediatr (2001) 1.35
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol (1991) 1.33
Genome structure and virion polypeptides of the primate herpesviruses Herpesvirus aotus types 1 and 3: comparison with human cytomegalovirus. J Virol (1983) 1.32
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Visual symmetry recognition by pigeons. Psychol Res (1982) 1.23
Detection of gas embolism by transesophageal echocardiography during laparoscopic cholecystectomy. Anesth Analg (1996) 1.23
[Guidelines for heart pacemaker therapy]. Z Kardiol (2005) 1.22
Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol (1992) 1.22
On auxotrophy for pyrimidines of respiration-deficient chick embryo cells. Eur J Biochem (1984) 1.22
Aortoesophageal fistula: repair with transluminal placement of a thoracic aortic stent-graft. J Vasc Interv Radiol (1997) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Radiation doses of collimated vs non-collimated cephalometric exposures. Dentomaxillofac Radiol (2003) 1.17
The cavitation threshold of human tissue exposed to 0.2-MHz pulsed ultrasound: preliminary measurements based on a study of clinical lithotripsy. Ultrasound Med Biol (1995) 1.17
Teaching preschool age autistic children to make spontaneous initiations to peers using priming. J Autism Dev Disord (1996) 1.12
Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2004) 1.11
Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg (2000) 1.11
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol (1996) 1.10
Measurement of the electron charge asymmetry in pp[over ]-->W+X-->enu+X events at sqrt[s]=1.96 TeV. Phys Rev Lett (2008) 1.09
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Evidence for a particle produced in association with weak bosons and decaying to a bottom-antibottom quark pair in higgs boson searches at the tevatron. Phys Rev Lett (2012) 1.08
First year of life after the use of atenolol in pregnancy associated hypertension. Arch Dis Child (1984) 1.08
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res (1987) 1.08
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Guide to the identification of fish protozoan and metazoan parasites in stained tissue sections. Dis Aquat Organ (2006) 1.07
Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2001) 1.07
Suppression of allergic reaction by lambda-carrageenan: toll-like receptor 4/MyD88-dependent and -independent modulation of immunity. Clin Exp Allergy (2003) 1.07
Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Cytometry (1982) 1.07
Unknown primary tumors metastatic to liver. J Clin Oncol (1998) 1.06
A defect in bone marrow derived dendritic cell maturation in the nonobesediabetic mouse. Clin Exp Immunol (2001) 1.05
Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine (2004) 1.05
Determination of the width of the top quark. Phys Rev Lett (2011) 1.05
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
Common bile duct exploration: the place of laparoscopic choledochotomy. Surg Laparosc Endosc (1994) 1.04
Search for large extra dimensions via single photon plus missing energy final states at sqrt s = 1.96 TeV. Phys Rev Lett (2008) 1.04
Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. J Antimicrob Chemother (2013) 1.03
Search for doubly charged Higgs boson pair production in pp¯ collisions at √s=1.96 TeV. Phys Rev Lett (2012) 1.02
The biology of unknown primary tumors. Semin Oncol (1993) 1.01
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol (1996) 1.01
Pelvic floor maximal strength using vaginal digital assessment compared to dynamometric measurements. Neurourol Urodyn (2004) 1.00
Characteristics of eccrine sweat gland activity in the footpad of the cat. J Appl Physiol (1966) 1.00
Evaluation of measurement strategies to increase the reliability of EMG indices to assess back muscle fatigue and recovery. J Electromyogr Kinesiol (2002) 1.00
Pelvic floor muscle function in continent and stress urinary incontinent women using dynamometric measurements. Neurourol Urodyn (2004) 0.99
Primary cutaneous aspergillosis caused by Aspergillus ustus following reduced-intensity stem cell transplantation. Ann Hematol (2002) 0.99
Measurement of the polarization of W bosons with large transverse momenta in W + jets events at the LHC. Phys Rev Lett (2011) 0.99
Phase shifts of the human circadian system and performance deficit during the periods of transition. II. West-East flight. Aerosp Med (1966) 0.99
Strategies for gallium removal after focused ion beam patterning of ferroelectric oxide nanostructures. Nanotechnology (2007) 0.99
Taurine chloramine down-regulates the generation of murine neutrophil inflammatory mediators. Immunopharmacology (1998) 0.98
Measurement of the inclusive jet cross section in pp collisions at √s = 7 TeV. Phys Rev Lett (2011) 0.98
Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol (1996) 0.98
Search for neutral minimal supersymmetric standard model Higgs bosons decaying to tau pairs in pp collisions at √s=7 TeV. Phys Rev Lett (2011) 0.97
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol (1997) 0.97
Diagnostic value of stored electrograms in single-lead VDD systems. Pacing Clin Electrophysiol (2000) 0.96
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol (1998) 0.96
Patent foramen ovale closure in patients with transient ischemia attack/stroke. J Interv Cardiol (2001) 0.96
Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol (2013) 0.96
Active site-directed double mutants of dihydrofolate reductase. Cancer Res (1996) 0.95
Depression, suicidal ideation, and substance use among adolescents. Are athletes at less risk? Arch Fam Med (1994) 0.95
Display of passenger proteins on the surface of Escherichia coli K-12 by the enterohemorrhagic E. coli intimin EaeA. J Bacteriol (2001) 0.95
Measurement of associated production of vector bosons and top quark-antiquark pairs in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2013) 0.95